Critical Reviews in Oncology / Hematology
Volume 77, Issue 1 , Pages 30-47, January 2011

Positron emission tomography and colorectal cancer

  • Michael Lin

      Affiliations

    • Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, Australia
    • University of New South Wales, Sydney, Australia
    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Corresponding Author InformationCorresponding author at: Department of Nuclear Medicine and PET, 1 Elizabeth Drive, Liverpool Hospital, Liverpool, New South Wales 2170, Australia. Tel.: +61 2 9828 3515; fax: +61 2 9828 3529.
  • ,
  • Karen Wong

      Affiliations

    • University of New South Wales, Sydney, Australia
    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Department of Radiation Oncology, Liverpool Hospital, Sydney, Australia
  • ,
  • Weng Leong Ng

      Affiliations

    • University of New South Wales, Sydney, Australia
    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Department of Medical Oncology, Liverpool Hospital, Sydney, Australia
  • ,
  • Ivan Ho Shon

      Affiliations

    • Department of Nuclear Medicine and PET, Liverpool Hospital, Sydney, Australia
    • University of New South Wales, Sydney, Australia
  • ,
  • Matthew Morgan

      Affiliations

    • South Western Sydney Colorectal Tumour Group, Sydney South West Area Health Service, Sydney, Australia
    • Department of Colorectal Surgery, Bankstown Hospital, Sydney, Australia

Accepted 30 April 2010. published online 12 July 2010.

Abstract 

Colorectal cancer (CRC) is a major cause of cancer-related morbidity and mortality. Molecular imaging using positron emission tomography (PET) is now an integral part of multidisciplinary cancer care. In this review, we discuss the role of PET in CRC including well established indications in the assessment of recurrent disease and emerging applications such as initial staging, monitoring therapy efficacy and using PET for radiotherapy planning. With rapid advancement in imaging technology, we also discuss the future potential of combining PET and magnetic resonance imaging and the use of novel radiotracers.

Keywords: Positron emission tomography, PET, FDG, Colorectal cancer, Oncology, Therapy response

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1040-8428(10)00119-8

doi:10.1016/j.critrevonc.2010.04.011

Critical Reviews in Oncology / Hematology
Volume 77, Issue 1 , Pages 30-47, January 2011